
BHC
Bausch Health Companies Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.900
Open
5.820
VWAP
5.76
Vol
760.13K
Mkt Cap
2.36B
Low
5.500
Amount
4.38M
EV/EBITDA(TTM)
7.68
Total Shares
366.80M
EV
23.69B
EV/OCF(TTM)
14.93
P/S(TTM)
0.26
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter (OTC) products and ophthalmic surgical devices and instruments. The Salix segment consists of sales in the U.S. of gastroenterology products. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Diversified segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Bausch + Lomb segment includes Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
2.68B
+4.79%
1.260
+8.62%
2.58B
+2.71%
1.158
+3.13%
2.48B
+3.01%
0.944
-4.07%
Estimates Revision
The market is revising Upward the revenue expectations for Bausch Health Companies Inc. (BHC) for FY2025, with the revenue forecasts being adjusted by 0.16% over the past three months. During the same period, the stock price has changed by 8.49%.
Revenue Estimates for FY2025
Revise Upward

+0.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-8.63%
In Past 3 Month
Stock Price
Go Up

+8.49%
In Past 3 Month
5 Analyst Rating

30.43% Upside
Wall Street analysts forecast BHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHC is 7.50 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
4 Hold
1 Sell
Hold

30.43% Upside
Current: 5.750

Low
5.00
Averages
7.50
High
10.00

30.43% Upside
Current: 5.750

Low
5.00
Averages
7.50
High
10.00
Jefferies
David Steinberg
Strong Buy
to
Hold
Downgrades
$12 → $8
2025-02-06
Reason
Jefferies
David Steinberg
Price Target
$12 → $8
2025-02-06
Downgrades
Strong Buy
to
Hold
Reason
Jefferies downgraded Bausch Health to Hold from Buy.
RBC Capital
Douglas Miehm
Hold
Maintains
$11 → $10
2025-01-30
Reason
RBC Capital
Douglas Miehm
Price Target
$11 → $10
2025-01-30
Maintains
Hold
Reason
RBC Capital lowered the firm's price target on Bausch Health (BHC) to $10 from $11 and keeps a Sector Perform rating on the shares ahead of its Q4 results. The firm is adjusting its model as it reduces the BLCO - Bausch + Lomb - sale scenario, weighting to 60% from 75% given the recent news of Blackstone (BX) likely dropping out of consortium with TPG to take out BLCO, the analyst tells investors in a research note.
RBC Capital
Douglas Miehm
Hold
Maintains
$10 → $11
2024-11-01
Reason
RBC Capital
Douglas Miehm
Price Target
$10 → $11
2024-11-01
Maintains
Hold
Reason
RBC Capital
Douglas Miehm
Hold
Maintains
$10 → $8.5
2024-08-02
Reason
RBC Capital
Douglas Miehm
Price Target
$10 → $8.5
2024-08-02
Maintains
Hold
Reason
Piper Sandler
David Amsellem
Hold
to
Sell
Downgrades
$9 → $3
2024-08-02
Reason
Piper Sandler
David Amsellem
Price Target
$9 → $3
2024-08-02
Downgrades
Hold
to
Sell
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bausch Health Companies Inc (BHC.N) is 1.65, compared to its 5-year average forward P/E of 3.49. For a more detailed relative valuation and DCF analysis to assess Bausch Health Companies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
3.49
Current PE
1.65
Overvalued PE
5.70
Undervalued PE
1.27
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
8.21
Current EV/EBITDA
6.73
Overvalued EV/EBITDA
9.24
Undervalued EV/EBITDA
7.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
0.57
Current PS
0.25
Overvalued PS
0.95
Undervalued PS
0.19
Financials
Annual
Quarterly
FY2025Q2
YoY :
+5.29%
2.53B
Total Revenue
FY2025Q2
YoY :
+491.02%
2.50B
Operating Profit
FY2025Q2
YoY :
-12900.00%
128.00M
Net Income after Tax
FY2025Q2
YoY :
-100.00%
N/A
EPS - Diluted
FY2025Q1
YoY :
-32.03%
87.00M
Free Cash Flow
FY2025Q1
YoY :
+0.16%
57.64
Gross Profit Margin - %
FY2025Q1
YoY :
+42.69%
12.50
FCF Margin - %
FY2025Q1
YoY :
+6.42%
-3.81
Net Margin - %
FY2025Q1
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
83.0K
USD
1
Bought
0-3
4
35.9M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
2.7M
Volume
3
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
4.2M
Volume
Months
6-9
2
3.5M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
83.0K
USD
1
Bought
0-3
4
35.9M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BHC News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
17:13:36
Bausch Health reports Q2 GAAP EPS 40c vs. 3c last year

2025-07-29 (ET)
2025-07-29
07:18:54
Bausch Health to acquire Durect for $1.75 per share in cash upfront

2025-07-29
07:02:53
Bausch Health to acquire Durect for $1.75 per share in an all-cash transaction

Sign Up For More Events
Sign Up For More Events
News
9.5
07-30Yahoo FinancePinnedBausch: Q2 Earnings Snapshot
9.5
00:00 AMNASDAQ.COMBausch Health (BHC) Lags Q2 Earnings Estimates
8.5
07-29BenzingaBausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Sign Up For More News
People Also Watch

GRBK
Green Brick Partners Inc
61.975
USD
-2.80%

STNG
Scorpio Tankers Inc
45.520
USD
-0.39%

MCY
Mercury General Corp
70.690
USD
0.00%

HUT
Hut 8 Corp
20.630
USD
+4.09%

FFBC
First Financial Bancorp
24.490
USD
0.00%

GT
Goodyear Tire & Rubber Co
10.023
USD
-1.45%

TBBK
Bancorp Inc
62.830
USD
-0.25%

YELP
Yelp Inc
34.830
USD
-0.20%

PSMT
PriceSmart Inc
107.140
USD
0.00%

PRVA
Privia Health Group Inc
19.590
USD
0.00%
FAQ

What is Bausch Health Companies Inc (BHC) stock price today?
The current price of BHC is 5.75 USD — it has decreased -10.02 % in the last trading day.

What is Bausch Health Companies Inc (BHC)'s business?

What is the price predicton of BHC Stock?

What is Bausch Health Companies Inc (BHC)'s revenue for the last quarter?

What is Bausch Health Companies Inc (BHC)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Bausch Health Companies Inc (BHC)'s fundamentals?

How many employees does Bausch Health Companies Inc (BHC). have?
